Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 04.05.2026 4 Aliment Pharmacol Ther 1 Am J Gastroenterol 1 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 1 Clin Res Hepatol Gastroenterol 1 Dig Dis 2 Dig Dis Sci 1 Dis Colon Rectum 1 Gastroenterology 7 Inflamm Bowel Dis 1 J Clin Gastroenterol 2 J Crohns Colitis 1 J Gastroenterol 1 Mediators Inflamm 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. GARCIA JLR, Suarez-Ferrer C, Zabana Y
   Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply.
   Aliment Pharmacol Ther. 2026 Apr 27. doi: 10.1111/apt.70702.
   PubMed        
   
   
2. RICHARD N, Seksik P, Altwegg R, Nachury M, et al
   One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.
   Aliment Pharmacol Ther. 2026 Apr 27. doi: 10.1111/apt.70682.
   PubMed         Abstract available
   
   
3. LI J
   Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Apr 25. doi: 10.1111/apt.70700.
   PubMed        
   
   
4. FONS AB, Asscher VER, Mooijaart SP, Maljaars PWJ, et al
   Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply.
   Aliment Pharmacol Ther. 2026 Apr 25. doi: 10.1111/apt.70660.
   PubMed        
   
   

   
   Am J Gastroenterol

5. LICHTENSTEIN GR, Allegretti JR, Rubin DT, Magro F, et al
   Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.
   Am J Gastroenterol. 2026 May 1. doi: 10.14309/ajg.0000000000004041.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

6. MOHAMEDRASHED M, Yogakanthi S, Bartlett R, Chew M, et al
   Early infliximab rescue therapy is associated with reduced length of stay in patients with acute severe ulcerative colitis.
   BMC Gastroenterol. 2026 Apr 27. doi: 10.1186/s12876-026-04847.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

7. SEO J, Kim S, Hong SW, Hwang SW, et al
   Impact of stopping thiopurines under anti-TNF therapy in inflammatory bowel disease: A population-based study.
   Clin Gastroenterol Hepatol. 2026 Apr 28:S1542-3565(26)00320.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

8. PITKANEN R, Pasternack C, Salmi T, Hervonen K, et al
   THE RISK OF INFLAMMATORY BOWEL DISEASE IS INCREASED IN CELIAC DISEASE BUT NOT IN DERMATITIS HERPETIFORMIS.
   Clin Res Hepatol Gastroenterol. 2026 Apr 23:102834.
   PubMed         Abstract available
   
   

   
   Dig Dis

9. HONJO K, Murakami K, Arai J, Ihara S, et al
   Predictive Factors for Abnormal Diagnostic Colonoscopy Findings among Pediatric Patients: A Retrospective Cohort Study.
   Dig Dis. 2026;44:216-224.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

10. VAN DER HAVE M, Kaptein AA
    Treating the Whole Disease: A Call for Holistic Care for Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2026 Apr 27. doi: 10.1007/s10620-026-09915.
    PubMed        
    
    
11. RAICH SS, Kaakoush NO
    Can Fecal Metabolites Provide Insight into the Heterogeneity of Crohn's Disease?
    Dig Dis Sci. 2026 Apr 25. doi: 10.1007/s10620-026-09936.
    PubMed        
    
    

    
    Dis Colon Rectum

12. XING J, Mei Z
    Mesenteric Adipose Radiomics for Structural Damage Stratification in Chronic Ulcerative Colitis.
    Dis Colon Rectum. 2026 Apr 29. doi: 10.1097/DCR.0000000000004275.
    PubMed        
    
    

    
    Gastroenterology

13. TAKEFUJI Y
    Evaluating Linear Parametric Poisson Regression vs Nonparametric Unsupervised Learning in Ulcerative Colitis Data.
    Gastroenterology. 2026 Apr 25:S0016-5085(26)06761.
    PubMed        
    
    

    
    Inflamm Bowel Dis

14. AFZALI A, Danese S, Panaccione R, Rubin DT, et al
    Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
    Inflamm Bowel Dis. 2026 May 1:izag055. doi: 10.1093.
    PubMed         Abstract available
    
    
15. PARK SS, Kim YJ, Ahn BK
    Extraintestinal manifestations in Korean patients with inflammatory bowel disease: A nationwide population-based study from 2005 to 2017.
    Inflamm Bowel Dis. 2026 Apr 30:izag068. doi: 10.1093.
    PubMed         Abstract available
    
    
16. PUCA P, Masi L, Parello S, Poscia A, et al
    OCTN1 variants shape innate immunity and predict individual response to anti-TNFalpha in ulcerative colitis patients: An exploratory study.
    Inflamm Bowel Dis. 2026 Apr 28:izag061. doi: 10.1093.
    PubMed         Abstract available
    
    
17. SLEIMAN J, El Ouali S, Noor NM
    Entering a new GALAXI: The importance of long-term data in Crohn's disease clinical trials.
    Inflamm Bowel Dis. 2026 Apr 25:izag073. doi: 10.1093.
    PubMed        
    
    
18. SHEEHAN JL, Eloubeidi D, Newman KL, Johnson LA, et al
    Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization.
    Inflamm Bowel Dis. 2026 Apr 25:izag062. doi: 10.1093.
    PubMed         Abstract available
    
    
19. GILBOA I, Gabbai D, Segal N, Gold R, et al
    Inflammatory bowel disease and risk of perineal injury in primiparous vaginal births: a retrospective cohort study.
    Inflamm Bowel Dis. 2026 Apr 25:izag067. doi: 10.1093.
    PubMed         Abstract available
    
    
20. GOYAL MK, Dutta P, Choy MC, Berinstein JA, et al
    Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.
    Inflamm Bowel Dis. 2026 Apr 24:izag042. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

21. NGUYEN B, Quon S, Ma C, Singh S, et al
    Comparative Outcomes After Index Myocardial Infarction in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Clin Gastroenterol. 2026 Apr 27. doi: 10.1097/MCG.0000000000002372.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

22. PELLY T, Anand E, Gower J, Mannick S, et al
    What are the top 10 global research priorities for perianal Crohn's disease? The Global Perianal Crohn's Disease Priority Setting Partnership.
    J Crohns Colitis. 2026;20:jjag018.
    PubMed         Abstract available
    
    
23. COLWILL M, Spencer A, Honap S
    Anogenital cutaneous Crohn's disease: effective treatment with interleukin-23 p19 inhibition in an under-recognized clinical entity.
    J Crohns Colitis. 2026;20:jjag047.
    PubMed        
    
    

    
    J Gastroenterol

24. AKIYAMA S, Tsuchiya K
    Reply to "Letter to "Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis"".
    J Gastroenterol. 2026 Apr 25. doi: 10.1007/s00535-026-02427.
    PubMed        
    
    

    
    Mediators Inflamm

25. SHI L, Jin G, Gao X, Chen Y, et al
    Evaluating Ribosomal Protein L19 mRNA as a Biomarker in Ulcerative Colitis: Implications for Severity Assessment.
    Mediators Inflamm. 2026;2026:e4823996.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

26. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo-Uixeda S
    Letter to the editor 'high persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study)'.
    Scand J Gastroenterol. 2026 Apr 29:1-2. doi: 10.1080/00365521.2026.2661965.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum